Evidence map›Paper›PMID 35862201›Full record

ArticleStroke2022

US Surveillance of Acute Ischemic Stroke Patient Characteristics, Care Quality, and Outcomes for 2019.

Boback Ziaeian, Haolin Xu, Roland A Matsouaka, Ying Xian, Yosef Khan, Lee S Schwamm, Eric E Smith, Gregg C Fonarow

Abstract read
In one paragraph

Article in Stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Toward development of a dynamic supramolecular peptide therapy for acute ischemic stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Boback ZiaeianDivision of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (B.Z., G.C.F.).ORCID 0000-0001-9787-3649
Haolin XuDuke Clinical Research Institute, Durham, NC (H.X., R.A.M.).ORCID 0000-0003-1069-9567
Roland A MatsouakaDuke Clinical Research Institute, Durham, NC (H.X., R.A.M.).ORCID 0000-0002-0271-5400
Ying XianDepartment of Neurology, UT Southwestern Medical Center, Dallas, TX (Y.X.).ORCID 0000-0002-1237-1162
Yosef KhanPremier Inc, Charlotte, NC (Y.K.).
Lee S SchwammDepartment of Neurology, Comprehensive Stroke Center Massachusetts General Hospital and Harvard Medical School, Boston (L.S.S.).ORCID 0000-0003-0592-9145
Eric E SmithDepartment of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.).ORCID 0000-0003-3956-1668
Gregg C FonarowDivision of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (B.Z., G.C.F.).ORCID 0000-0002-3192-8093

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Balancing Risks and Benefits of Direct Oral Anticoagulants in Older Ischemic Stroke Patients with Atrial FibrillationR01AG066672 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI XIAN, YING · 2020 to 2025
$2.6M
Antiplatelet in Stroke: Safety and Effectiveness in Seniors (ASSESS)R01AG062770 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI XIAN, YING · 2019 to 2023
$2.2M
American Heart Association-American Stroke Association 17SDG33630113NCATS NIH HHS KL2 TR001882NIA NIH HHS R01 AG062770NIA NIH HHS R01 AG066672
6 · The paper itself

Abstract

backgroundThe United States lacks a timely and accurate nationwide surveillance system for acute ischemic stroke (AIS). We use the Get With The Guidelines-Stroke registry to apply poststratification survey weights to generate national assessment of AIS epidemiology, hospital care quality, and in-hospital outcomes.

methodsClinical data from the Get With The Guidelines-Stroke registry were weighted using a Bayesian interpolation method anchored to observations from the national inpatient sample. To generate a US stroke forecast for 2019, we linearized time trend estimates from the national inpatient sample to project anticipated AIS hospital volume, distribution, and race/ethnicity characteristics for the year 2019. Primary measures of AIS epidemiology and clinical care included patient and hospital characteristics, stroke severity, vital and laboratory measures, treatment interventions, performance measures, disposition, and clinical outcomes at discharge.

resultsWe estimate 552 476 patients with AIS were admitted in 2019 to US hospitals. Median age was 71 (interquartile range, 60-81), 48.8% female. Atrial fibrillation was diagnosed in 22.6%, 30.2% had prior stroke/transient ischemic attack, and 36.4% had diabetes. At baseline, 46.4% of patients with AIS were taking antiplatelet agents, 19.2% anticoagulants, and 46.3% cholesterol-reducers. Mortality was 4.4%, and only 52.3% were able to ambulate independently at discharge. Performance nationally on AIS achievement measures were generally higher than 95% for all measures but the use of thrombolytics within 3 hours of early stroke presentations (81.9%). Additional quality measures had lower rates of receipt: dysphagia screening (84.9%), early thrombolytics by 4.5 hours (79.7%), and statin therapy (80.6%).

conclusionsWe provide timely, reliable, and actionable US national AIS surveillance using Bayesian interpolation poststratification weights. These data may facilitate more targeted quality improvement efforts, resource allocation, and national policies to improve AIS care and outcomes.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsIschemic StrokeStrokeAgedAnticoagulantsBayes TheoremFemaleFibrinolytic AgentsHumansMalePlatelet Aggregation InhibitorsQuality of Health CareTreatment OutcomeUnited StatesAnticoagulantsFibrinolytic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsBayesian analysisepidemiologyhealth servicesischemic strokequality and outcomes

Identifiers

PMID35862201
PMCPMC9613506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.